A novel oral 5HT2A inverse agonist for the treatment of psychosis associated with Parkinson disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
A novel oral 5HT2A inverse agonist for the treatment of psychosis associated with Parkinson disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.